Stanley-Laman Group’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $712K | Sell |
5,916
-2,215
| -27% | -$256K | 0.09% | 189 |
|
|
2025
Q4 | $856K | Buy |
8,131
+5,413
| +199% | +$508K | 0.11% | 178 |
|
|
2025
Q3 | $228K | Sell |
2,718
-1,012
| -27% | -$83.4K | 0.03% | 241 |
|
|
2025
Q2 | $295K | Sell |
3,730
-3,084
| -45% | -$245K | 0.04% | 239 |
|
|
2025
Q1 | $612K | Buy |
6,814
+2,833
| +71% | +$265K | 0.09% | 179 |
|
|
2024
Q4 | $396K | Sell |
3,981
-2,043
| -34% | -$211K | 0.06% | 221 |
|
|
2024
Q3 | $684K | Buy |
6,024
+979
| +19% | +$116K | 0.1% | 183 |
|
|
2024
Q2 | $625K | Buy |
5,045
+1,367
| +37% | +$176K | 0.09% | 176 |
|
|
2024
Q1 | $485K | Hold |
3,678
| – | – | 0.07% | 187 |
|
|
2023
Q4 | $401K | Buy |
3,678
+219
| +6% | +$22.7K | 0.06% | 194 |
|
|
2023
Q3 | $356K | Buy |
3,459
+3
| +0.1% | +$323 | 0.06% | 189 |
|
|
2023
Q2 | $399K | Buy |
3,456
+7
| +0.2% | +$795 | 0.07% | 185 |
|
|
2023
Q1 | $367K | Buy |
+3,449
| New | +$372K | 0.07% | 185 |
|
|
2021
Q1 | – | Sell |
-21,526
| Closed | -$1.68M | – | 256 |
|
|
2020
Q4 | $1.68M | Buy |
21,526
+4,499
| +26% | +$344K | 0.3% | 100 |
|
|
2020
Q3 | $1.35M | Sell |
17,027
-1,618
| -9% | -$127K | 0.3% | 97 |
|
|
2020
Q2 | $1.38M | Buy |
18,645
+754
| +4% | +$56.8K | 0.33% | 82 |
|
|
2020
Q1 | $1.31M | Buy |
17,891
+2,655
| +17% | +$209K | 0.4% | 66 |
|
|
2019
Q4 | $1.32M | Sell |
15,236
-677
| -4% | -$55.6K | 0.31% | 98 |
|
|
2019
Q3 | $1.28M | Sell |
15,913
-1,381
| -8% | -$111K | 0.32% | 91 |
|
|
2019
Q2 | $1.38M | Buy |
17,294
+1,005
| +6% | +$77K | 0.33% | 87 |
|
|
2019
Q1 | $1.29M | Buy |
16,289
+530
| +3% | +$39.6K | 0.31% | 91 |
|
|
2018
Q4 | $1.15M | Sell |
15,759
-512
| -3% | -$36.1K | 0.32% | 91 |
|
|
2018
Q3 | $1.1M | Sell |
16,271
-8,011
| -33% | -$510K | 0.27% | 114 |
|
|
2018
Q2 | $1.41M | Buy |
24,282
+3,286
| +16% | +$185K | 0.32% | 93 |
|
|
2018
Q1 | $1.09M | Buy |
20,996
+157
| +0.8% | +$8.48K | 0.25% | 114 |
|
|
2017
Q4 | $1.12M | Buy |
20,839
+11,588
| +125% | +$642K | 0.24% | 110 |
|
|
2017
Q3 | $565K | Sell |
9,251
-922
| -9% | -$55.9K | 0.15% | 166 |
|
|
2017
Q2 | $622K | Hold |
10,173
| – | – | 0.17% | 126 |
|
|
2017
Q1 | $617K | Sell |
10,173
-6,923
| -40% | -$420K | 0.17% | 143 |
|
|
2016
Q4 | $960K | Sell |
17,096
-5,570
| -25% | -$326K | 0.3% | 116 |
|
|
2016
Q3 | $1.35M | Sell |
22,666
-9,834
| -30% | -$575K | 0.55% | 41 |
|
|
2016
Q2 | $1.79M | Sell |
32,500
-31,714
| -49% | -$1.69M | 0.7% | 33 |
|
|
2016
Q1 | $3.24M | Sell |
64,214
-1,533
| -2% | -$75.1K | 0.61% | 39 |
|
|
2015
Q4 | $3.31M | Buy |
65,747
+299
| +0.5% | +$15.1K | 0.57% | 55 |
|
|
2015
Q3 | $3.08M | Hold |
65,448
| – | – | 0.63% | 47 |
|
|
2015
Q2 | $3.56M | Sell |
65,448
-104
| -0.2% | -$5.83K | 0.65% | 50 |
|
|
2015
Q1 | $3.6M | Buy |
65,552
+1,196
| +2% | +$67.7K | 0.66% | 50 |
|
|
2014
Q4 | $3.49M | Buy |
64,356
+3,106
| +5% | +$173K | 0.66% | 49 |
|
|
2014
Q3 | $3.46M | Buy |
61,250
+592
| +1% | +$33.2K | 0.67% | 48 |
|
|
2014
Q2 | $3.35M | Sell |
60,658
-934
| -2% | -$51K | 0.61% | 53 |
|
|
2014
Q1 | $3.34M | Buy |
+61,592
| New | +$3.19M | 0.58% | 59 |
|
Other funds holding MRK
VCM
VPM
Stanley-Laman Group's MRK Position: Q1 2026 in Review
Stanley-Laman Group reduced its Merck (MRK) stake by 27% in Q1 2026, selling an estimated $256K and leaving 5,916 shares worth $712K. The position accounts for 0.09% of the portfolio, ranked #189.
Stanley-Laman Group first reported a position in MRK in Q1 2014 and has held it in 41 quarters since. The position peaked at $3.6M in Q1 2015. 3,780 funds tracked by Wall St. Rank hold MRK as of Q1 2026.
- Stanley-Laman Group held 5,916 shares of Merck worth $712K as of Q1 2026.
- Stanley-Laman Group sold 2,215 Merck shares in Q1 2026, an estimated $256K.
- Merck made up 0.09% of Stanley-Laman Group's portfolio in Q1 2026, its #189 holding.
- Stanley-Laman Group first reported a position in Merck in Q1 2014 and has held it in 41 quarters since.
- Stanley-Laman Group's Merck position peaked at $3.6M in Q1 2015.
- 3,780 funds tracked by Wall St. Rank held Merck as of Q1 2026.
Based on Stanley-Laman Group's 13F filing for Q1 2026, filed 16 Apr 2026.